# Pathway Peptide reference shelf

> Published studies | Pathway Peptide — The Pathway Peptide reading list: published studies of CJC-1295 hormone dynamics, semaglutide outcomes, thymosin alpha-1 and BPC-157 experiments.

Original experiments, patient trials and reviews from the four investigations.

## Suggested starting papers

For the timing question, start with [Ionescu and Frohman on persistent GH pulses](https://pubmed.ncbi.nlm.nih.gov/17018654/), then [Teichman and colleagues on prolonged GH and IGF-1 secretion](https://pubmed.ncbi.nlm.nih.gov/16352683/). The [serum-protein study](https://pubmed.ncbi.nlm.nih.gov/19386527/) adds a smaller, exploratory view of the downstream response.

Semaglutide's [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/), [SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/) and [FLOW](https://pubmed.ncbi.nlm.nih.gov/38785209/) ask about different populations and outcomes. The [safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) deserves a place beside them. Thymosin alpha-1's [TESTS trial](https://pubmed.ncbi.nlm.nih.gov/39814420/) supplies the demanding sepsis comparison, while the [dendritic-cell paper](https://pubmed.ncbi.nlm.nih.gov/16741252/) investigates immune regulation.

In the BPC-157 literature, the [VEGFR2 experiment](https://pubmed.ncbi.nlm.nih.gov/27847966/) and the [2025 review of musculoskeletal research](https://pubmed.ncbi.nlm.nih.gov/40789979/) make a useful pair: a specific mechanistic result alongside the limits of the human record. The complete source list follows.

## References

[1] Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. https://pubmed.ncbi.nlm.nih.gov/39814420/
[2] Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020. https://pubmed.ncbi.nlm.nih.gov/33362999/
[3] Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020. https://pubmed.ncbi.nlm.nih.gov/32442287/
[4] Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. https://pubmed.ncbi.nlm.nih.gov/31555601/
[5] Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013. https://pubmed.ncbi.nlm.nih.gov/23327199/
[6] Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006. https://pubmed.ncbi.nlm.nih.gov/16741252/
[7] Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977. https://pubmed.ncbi.nlm.nih.gov/265536/
[8] Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[9] Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/
[10] Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
[11] Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
[12] Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/34305810/
[13] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[14] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[15] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[16] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[17] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[18] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[19] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[20] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[21] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[22] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/

---

Pathway Peptide independently audits receptor signals, downstream markers and outcome claims; it is a literature briefing, not clinical direction.